Eiger BioPharmaceuticals has received a recommendation from the Data Safety Monitoring Board (DSMB) to continue the Phase III TOGETHER clinical trial of Peginterferon Lambda without any changes.

The advice comes after DSMB carried out a second interim futility assessment on a sample size of 1,003 subjects randomised to receive the treatment or placebo.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The DSMB, which offers independent trial insight, previously recommended discontinuing five other therapies due to futility.

A type III interferon (IFN), Peginterferon Lambda induces immune responses required to develop host protection at the time of viral infections.

In 2016, Eiger obtained global rights to the therapy from Bristol-Myers Squibb.

The investigator-sponsored, multicentre, randomised, placebo-controlled adaptive platform trial is assessing Peginterferon Lambda in recently diagnosed Covid-19 non-hospitalised patients who are at greater risk.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It will enrol nearly 1,600 subjects with recruitment underway at 12 trial centres in Brazil.

Participants will be randomised to receive Peginterferon Lambda or a placebo.

The number of emergency setting visits, hospital admission and/or mortality through day 28 is the primary goal of the trial.

Eiger president and CEO David Cory said: “Peginterferon Lambda stimulates immune responses critical to innate defences with a mechanism of action agnostic to variants of SARS-CoV-2 and resistance concerns with other treatments.

“A single subcutaneous injection of Peginterferon Lambda administered to newly diagnosed Covid-19 patients may reduce complications and prevent hospitalizations, with or without other treatments.”

This July, the company dosed the first Covid-19 patients in the Phase III TOGETHER trial of Peginterferon Lambda in outpatient settings.